ERBB2 and breast carcinoma: This study cohort reports the treatment patterns and HRCU for TNBC from 2014 to 2017, therefore it doesn’t include the new technologies that were approved into the disease landscape, for instance: the PARP inhibitors were approved in 2019 and 2022 (for advanced and early stage gBRCAm HER2- Breast Cancer, respectively) but, still there is restriction to its use in either setting because an additional HTA assessment is required for oral drugs incorporation into private health sector25,26,40,41.